The burden of HIV-related stigma on clinical and quality of life outcomes: results from a systematic literature review Authors: Irina Kolobova, Natalya Danchenko, Ian Jacob, Dennis Rice, Shannon Jones, Emily Matthews, Patrice Carter, Sanjeev Kumar Bhopal, Michelle Moorhouse Published: 2026 ABSTRACT AbstractBackgroundHIV-related stigma adversely impacts people with HIV. As part of a systematic literature review (SLR) to evaluate 6 research questions on HIV-related stigma among people with HIV, data from studies examining its prevalence and association with clinical and quality of life (QoL) outcomes are presented.MethodsSearches were conducted in MEDLINE® and Embase® via the OVID platform from May 2020 to May 2023 for prevalence and from database inception to May 2023 for the other 5 research questions. Relevant conferences, SLR bibliographies, and websites were searched from January 2021 to June 2023. Records were independently screened by 2 reviewers until ≥90% inter-rater reliability was achieved. Data were extracted by 1 reviewer and validated by another.ResultsThe reported prevalence of HIV-related stigma was broad across multiple stigma types and geographic regions, ranging from 11% to 94%. Most identified studies reported significant associations between higher HIV-related stigma levels and reduced HIV-specific healthcare engagement and retention (8/11), suboptimal antiretroviral therapy adherence (16/20), unsuppressed viral load (10/14), high levels of substance use (3/4), and suboptimal mental health (28/30). Most identified studies reported significant associations between higher HIV-related stigma levels and poorer QoL (23/27).ConclusionsThe substantial evidence identified by this SLR suggests that HIV-related stigma is a significant challenge for people with HIV and negatively impacts QoL, mental health, and clinical outcomes. These findings underscore the importance of integrating stigma considerations into the dialogue between physicians and people with HIV to foster shared decision-making for treatment and support. Introduction Advancements in antiretroviral therapy (ART) have improved prognoses among people with HIV (UNAIDS, 2018; Vitoria et al., 2019); however, people with HIV still experience discrimination and HIV-related stigma (Hedge et al., 2021). HIV-related stigma is the negative attitudes and beliefs about people with HIV, whereas discrimination is the behaviour that stems from those attitudes and beliefs (Centers for Disease Control Prevention, 2024). HIV-related stigma is recognised as a global public health concern, and the Joint United Nations Programme on HIV and AIDS (UNAIDS) has established 10-10-10 targets for 2025 to remove social and legal obstacles that limit access to and utilisation of HIV services, with the aim that ‘less than 10% of people living with HIV and key populations experience stigma and discrimination’ (UNAIDS, 2020). However, across geographies and populations with HIV, HIV-related stigma remains unacceptably high (UNAIDS, 2020). A recent meta-analysis of 40 studies in 13 countries reported an HIV-related stigma prevalence range of 19% to 88%, with 44% (69,978/171,627) of people with HIV reporting high stigma levels (Dessie & Zewotir, 2024). There are multiple forms of HIV-related stigma (Figure 1) (Alemu et al., 2022; Earnshaw & Chaudoir, 2009; Liu et al., 2020; UNAIDS, n.d.; United States Agency for International Development 2006), all of which can impact people with HIV across multiple aspects of their lives (Charles et al., 2012; Tran et al., 2019). HIV-related stigma can affect the full HIV care continuum from testing, treatment initiation, and adherence, to maintaining viral suppression in people with HIV (Stutterheim et al., 2022). Among people with HIV in Zambia and the Western Cape of South Africa, individuals who reported enacted or internalised stigma were significantly more likely to be non-adherent to ART than those who did not (N = 2020; P ≤ 0.03) (Jones et al., 2020). Furthermore, a study conducted in the United States found that people with HIV (N = 80) were more likely to report enacted stigma if they had a viral load > 5000 versus ≤ 5000 copies/mL (odds ratio [OR; 95% CI], 2.02 [0.96, 4.29]; P = 0.05) (Amico et al., 2021). Forms of HIV-related stigma. aDefinitions may be author-dependent, and terms may be interchangeable or partially overlap within publications (Earnshaw & Chaudoir, 2009; Liu et al., 2020; United States Agency for International Development, 2006; UNAIDS; Alemu et al., 2022) HIV-related stigma is associated with feelings of shame, depression, anxiety, and lower quality of life (QoL) (Charles et al., 2012; Tran et al., 2019). Depression is the most common mental health disorder in people with HIV and is correlated with experiences of HIV-related stigma (Dave, 2024; Fuenmayor & Cournos, 2022). Earnshaw et al. found that internalised and enacted stigma were significantly associated with depressive symptoms, and that depressive symptoms were significantly associated with substance use (P < 0.01) in people with HIV in the United States (Earnshaw et al., 2020). Notably, substance and alcohol use can lead to worsened disease outcomes including poor QoL and disease progression (Dave, 2024). Among 3991 self-reported people with HIV, the odds (95% CI) of reporting problems in ≥1 health-related QoL domain were 2.10 (1.72, 2.56; P < 0.001) times higher if a participant experienced HIV-related stigma at least once, compared with never experiencing HIV-related stigma (Hall et al., 2024). In a systematic literature review (SLR) and meta-analysis of 64 articles, Rzeszutek et al reported a negative association between HIV-related stigma and subjective well-being (Pearson r [95% CI], −0.31 [−0.36, −0.26]) (Rzeszutek et al., 2021). In addition to associations with depression and lower QoL, HIV-related stigma and discrimination affect employment in people with HIV. Findings from the People Living with HIV Stigma Index study, which included data from 13 countries across 4 regions, revealed 13% to 100% of participants in Fiji and Timor-Leste, respectively, lost their jobs or sources of income as a result of HIV-related stigma and discrimination (Internal Labour Organisation, 2018). Together, these data highlight the complexity and negative consequences of HIV-related stigma. Due in part to its multi-faceted nature, there is no consensus on how to measure HIV-related stigma, leading to a complex body of research and unclear implications for future mitigation strategies and policy-making. In an effort to identify up-to-date published evidence to inform the current HIV-related stigma landscape from a global perspective, this SLR reports results from 4 research questions related to the association of HIV-related stigma with clinical and QoL outcomes, including healthcare engagement, ART adherence, viral suppression, comorbid conditions, and substance use, among people with HIV. Materials and methods Research questions This article presents findings from the following 4 research questions: What patient-reported outcome measures (PROMs) are used to assess HIV-related stigma in randomised controlled trials (RCTs) and observational studies?What is the prevalence of HIV-related stigma reported across international geographies?What published evidence is available on the association between HIV-related stigma and:Treatment concepts (e.g. adherence, retention in care)Clinical outcomes (e.g. viral suppression, CD4+ cell count)Mental health (e.g. depression)Health-related quality of life (HRQoL)Employment and educationWhat published evidence is available on the impact of HIV-related stigma on:Medication use for comorbid conditionsEconomic outcomes (e.g. healthcare resource utilisation)Drug, substance, and alcohol use What patient-reported outcome measures (PROMs) are used to assess HIV-related stigma in randomised controlled trials (RCTs) and observational studies? What patient-reported outcome measures (PROMs) are used to assess HIV-related stigma in randomised controlled trials (RCTs) and observational studies? What is the prevalence of HIV-related stigma reported across international geographies? What is the prevalence of HIV-related stigma reported across international geographies? What published evidence is available on the association between HIV-related stigma and:Treatment concepts (e.g. adherence, retention in care)Clinical outcomes (e.g. viral suppression, CD4+ cell count)Mental health (e.g. depression)Health-related quality of life (HRQoL)Employment and education What published evidence is available on the association between HIV-related stigma and: Treatment concepts (e.g. adherence, retention in care) Treatment concepts (e.g. adherence, retention in care) Clinical outcomes (e.g. viral suppression, CD4+ cell count) Clinical outcomes (e.g. viral suppression, CD4+ cell count) Mental health (e.g. depression) Mental health (e.g. depression) Health-related quality of life (HRQoL) Health-related quality of life (HRQoL) Employment and education Employment and education What published evidence is available on the impact of HIV-related stigma on:Medication use for comorbid conditionsEconomic outcomes (e.g. healthcare resource utilisation)Drug, substance, and alcohol use What published evidence is available on the impact of HIV-related stigma on: Medication use for comorbid conditions Medication use for comorbid conditions Economic outcomes (e.g. healthcare resource utilisation) Economic outcomes (e.g. healthcare resource utilisation) Drug, substance, and alcohol use Drug, substance, and alcohol use Search strategy and inclusion/exclusion criteria This SLR was conducted in alignment with PRISMA guidelines (Page et al., 2021) and a detailed protocol was registered with PROSPERO (CRD42023423538) (Carter et al., n.d.). Searches were conducted in MEDLINE® and Embase® via the OVID platform from May 2020 to May 2023 for the prevalence research question and from database inception to May 2023 for the other research questions. A restricted 3-year date range was applied to the prevalence search question to accurately capture the contemporary burden of HIV-related stigma. Conversely, searches for PROMs and clinical/economic associations were conducted from database inception to ensure a comprehensive capture of all foundational evidence. Conference proceedings and supplemental searches of European AIDS Treatment Group, National AIDS Trust, and European Centre of Disease Prevention and Control were conducted from 2021 to 2023. This search of conference proceedings and organisational websites were restricted to January 2021 to June 2023 to identify emerging, unpublished data and active guidelines while avoiding the duplication of older conference abstracts that have since been published as peer-reviewed manuscripts. Search strategies were developed using a combination of indexed keywords and free text terms to identify relevant literature. For each search, specific medical subject headings and keyword terms were employed for HIV/AIDS, HIV-related stigma, and clinical and QoL outcomes (Supplemental Tables 1–4). Table 1.Summary of studies reporting the prevalence of HIV-related stigma.PublicationPopulation (N)Tool used to measure HIV-related stigmaType of HIV-related stigma assessedDescription of toolMeasure of prevalenceReported prevalence (%)Drumright et al. (2023), United StatesPeople with HIV (6123)NRInternalised4 items rated on a 5-point Likert scale (low (Vitoria et al., 2019) to high (UNAIDS, 2020))Score of >2 with no change in score between 2 time periods (1 year apart from 2016-2022)11Pearson et al. (2021), United StatesPeople with HIV (5968)HIV Stigma Framework Scale (subscale)Internalised4 items rated on a 5-point Likert scale (strongly disagree (Vitoria et al., 2019) to strongly agree (UNAIDS, 2020))Participants who agreed or strongly agreed with ≥1 item29Kota et al. (2023), United StatesTransgender women with HIV (217)MMP survey (3 items from the HIV stigma scale [negative self-image subscale])Internalised3 items rated on a 5-point Likert scale (strongly disagree (Vitoria et al., 2019) to strongly agree (UNAIDS, 2020))Participants who somewhat agreed or strongly agreed with ≥1 item27MMP survey (3 items from the HIV stigma scale [personalised stigma subscale])Personalised52MMP survey (4 items from the HIV stigma scale [disclosure concerns and concerns with public attitudes])Anticipated4 items rated on a 5-point Likert scale (strongly disagree (Vitoria et al., 2019) to strongly agree (UNAIDS, 2020))Disclosure concerns: 87 Concerns with public attitudes: 69MMP survey (10 items from the HIV stigma scale [4 subscales: personalised stigma, disclosure concerns, negative self-image, concerns with public attitudes])Unspecified10 items rated on a 5-point Likert scale (strongly disagree (Vitoria et al., 2019) to strongly agree (UNAIDS, 2020))94Williams et al. (2022), United StatesPeople with HIV (603)HIV stigma scale (negative self-image subscale)Internalised3 items rated on a 5-point Likert scale (strongly disagree (Vitoria et al., 2019) to strongly agree (UNAIDS, 2020))a Participants who reported higher HIV-related stigma levels35HIV stigma scale (personalised stigma subscale)Personalised57HIV stigma scale (anticipated stigma subscale)Anticipated4 items rated on a 5-point Likert scale (strongly disagree (Vitoria et al., 2019) to strongly agree (UNAIDS, 2020))a 54HIV stigma scale (3 subscales: negative self-image, personalised stigma, anticipated stigma)Unspecified10 items rated on a 5-point Likert scale (strongly disagree (Vitoria et al., 2019) to strongly agree (UNAIDS, 2020))a 54Noori et al. (2022), EuropePeople with HIV (3272)ECDC, EATG, and AAE developed stigma surveyInternalised3 items rated on a 5-point Likert scale (strongly disagree (Vitoria et al., 2019) to strongly agree (UNAIDS, 2020))Participants who agreed or strongly agreed with each stigma itemRange: 27–57Enacted6 questions to assess experienced stigma from family and friends and recency of experienceParticipants who responded positively to each itemRange: 10–24Zhang et al. (2015), ChinaPeople with HIV (2987)AIDS-related stigma scaleInternalised8 items rated on a 4-point Likert scale (strongly disagree (Vitoria et al., 2019) to strongly agree (Prevention, 2024))Participants who agreed or strongly agreed with ≥1 item72Algarin et al. (2020), United StatesPeople with HIV (932)Herek HIV-related stigma measure (abbreviated)Enacted10 items rated on a 4-point Likert scaleParticipants who reported low/moderate or high enacted stigma levels53Maragh-Bass et al. (2021), United StatesPeople with HIV (937)Author-developed measureEnacted8 questions (yes/no) with an index range of 0–8b Participants reporting 1–3 types of HIV stigma-related non-disclosure experienceRange: 17–33Stutterheim et al. (2022), EuropePeople with HIV (137–649)Author-developed measureEnacted16 items rated on a 5-point Likert scale to measure 16 different settings (never (Vitoria et al., 2019) to very often (UNAIDS, 2020)); recoded to ‘never’ or ‘ever’Participants who reported ever experiencing stigma in each of the 16 settings assessedRange: 12–71Wiginton et al. (2021), EuropePeople with HIV (3475)Positive voices survey (included 1 item from the HIV Stigma Index) Enacted1 question to assess enacted stigma in the healthcare setting (yes/no)Participants who responded positively to the statement(s)19Perceived11Positive voices survey (included 2 items from the HIV Stigma Index)Anticipated2 questions to assess anticipated stigma in the healthcare setting (yes/no)Range: 17–35Positive voices survey (included 4 items from the HIV Stigma Index)Unspecified4 questions to assess overall stigma in the healthcare setting (yes/no)Participants who responded positively to ≥1 statement40Kall et al. (2020), EuropeMen with HIV (3110)Positive voices survey (included 1 item from the HIV Stigma Index)Enacted1 question to assess enacted stigma in the healthcare setting in the past year (yes/no)Participants who responded positively to experiencing stigma in the past year7Women with HIV (1208)9Transgender/non-binary people with HIV (39)13Men with HIV (3110)Positive voices survey (included 2 items from the HIV Stigma Index)Anticipated2 questions to assess anticipated stigma in the healthcare setting in the past year (yes/no)Participants who responded positively to anticipating stigma in the past yearRange: 8–14Women with HIV (1208)Range: 13–21Transgender/non-binary people with HIV (39)Range: 13–15Men with HIV (3110)Positive voices survey (included 1 item from the HIV Stigma Index)Perceived1 question to assess perceived stigma in the healthcare setting in the past year (yes/no)Participants who responded positively to perceiving stigma in the past year4Women with HIV (1208)7Transgender/non-binary people with HIV (39)12Brandelli Costa et al. (2022), BrazilPeople with HIV (1786)Stigma Index Brazil surveyEnactedMultiple-answer question (7 different discriminatory experiences from health facility staff)Participants who gave a positive response to any item15Kampouri et al. (2021), EuropePeople with HIV (5563)HIV stigma scale (disclosure concerns subscale)Anticipated12 items rated on a 4-point Likert scaleParticipants who responded positively to any item78Beltran et al. (2020), United StatesMen with HIV who have sex with men (NR)Single statement as part of the NHBS surveyPerceivedSingle statement used as an indicator of perceived stigmaParticipants who agreed or strongly agreed with the single statement2011: 192014: 162017: 23Bayes-Marin et al. (2023), EuropePeople with HIV (1060)Neuro-QOL Item Bank v1.0-stigmaPerceived2 questions used to assess self-perceived stigma in healthcare centresParticipants who responded positively to each statementRange: 13–20AAE; AIDS Action Europe; EATG, European AIDS Treatment Group; ECDC, European Centre for Disease Prevention and Control; MMP, Medical Monitoring Project; NHBS, National HIV Behavioural Surveillance; Neuro-QOL, Quality of Life in Neurological Disorders Item Bank v1.0 – Stigma; NR, not reported.aA categorical measure was created based on the median score (higher stigma and lower stigma). bDue to response distribution, categorical variables were assigned from 0–3 (0 = no stigma type, 1 = 1 stigma type, 2 = 2 stigma types, 3 = ≥3 stigma types). Summary of studies reporting the prevalence of HIV-related stigma. AAE; AIDS Action Europe; EATG, European AIDS Treatment Group; ECDC, European Centre for Disease Prevention and Control; MMP, Medical Monitoring Project; NHBS, National HIV Behavioural Surveillance; Neuro-QOL, Quality of Life in Neurological Disorders Item Bank v1.0 – Stigma; NR, not reported. A categorical measure was created based on the median score (higher stigma and lower stigma). bDue to response distribution, categorical variables were assigned from 0–3 (0 = no stigma type, 1 = 1 stigma type, 2 = 2 stigma types, 3 = ≥3 stigma types). Table 2.Summary of studies assessing the association of HIV-related stigma and initiation of HIV care or healthcare engagement and retention.PublicationStudy designForm of HIV-related stigmaOutcomeRegression logistic (high vs low stigma levels), OR (95% CI) P value (<0.05 considered statistically significant) Unadjusted analysis Kerrigan et al. (2017), BrazilCross-sectionalUnspecifiedMissed HIV care and treatment visits1.43 (1.09, 1.89)<0.05Takada et al. (2020), United StatesCross-sectionalUnspecifiedEngagement with HIV care (≥1 HIV primary care visit) 12 months before entering jail0.79 (0.53, 1.19)>0.05Pearson et al. (2021), United StatesCross-sectionalInternalisedAttendance at next HIV primary care appointment after stigma assessment0.89 (0.84, 0.95)<0.0001Attendance at all HIV primary care appointments in next 12 months after stigma assessment0.86 (0.82, 0.91)<0.0001Reif et al. (2019), United StatesCross-sectionalInternalisedMissed HIV care appointment in last 6 months0.59 (0.14)a <0.05Petroll et al. (2023), United StatesCross-sectionalPerceivedb Lower engagement with HIV care1.05 (NR)0.84Perceivedc 1.59 (NR)<0.001Wiginton et al. (2021), EuropeCross-sectionalUnspecified (overall)Reported unmet needs in peer support1.37 (1.30, 1.44)d NRReported unmet needs in access to chronic health conditions management1.43 (1.35, 1.50)d NRReported unmet needs in access to psychological care1.44 (1.37, 1.52)d NRReported unmet needs in access to isolation help1.45 (1.38, 1.53)d NR Adjusted analysis Christopoulos et al. (2019), United StatesCross-sectionalInternalisedPoor HIV care retention (≥2 missed primary care visits in prior year)1.12 (1.05, 1.20)e 0.001Lack of 6-month primary care visit consistency (as part of HIV care)1.09 (1.02, 1.17)e 0.008Hussen et al. (2015), United StatesCross-sectionalInternalised≥1 missed doctors’ appointments in last 3 months (as part of HIV care)0.95 (0.91, 0.99)0.03Molina et al. (2018), United StatesCross-sectionalEnactedRegular breast healthcare engagement (reporting clinical breast exam once in a year)0.97 (0.93, 1.01)f 0.17Internalised0.95 (0.91, 0.99)f 0.02 Logistic (low vs high stigma levels) Yigit et al. (2020), United StatesProspectiveInternalisedHIV visit adherence in the 48-week study period2.17 (1.09, 4.35)g 0.03 Unstandardised linear (high vs low stigma levels), β value (SE) Rice et al. (2017), United StatesCross-sectionalInternalisedLower HIV visit adherence–0.04 (0.02)0.04Petroll et al. (2023), United StatesCross-sectionalPerceivedb Low engagement in HIV care0.05 (0.24)NRPerceivedc 0.46 (0.10)NRCNICS, Centre for AIDS Research (CFAR) Network of Integrated Clinical Systems; NR, not reported; OR, odds ratio.aStandard error. b33-item HIV stigma scale used to measure perceived stigma. cHIV barriers to care scale (perceived stigma against people with HIV in their community: 1 item) used to measure perceived stigma. dUnadjusted prevalence ratio (endorsing stigma vs not endorsing stigma). eAdjusted for age, gender identity, sexual orientation, race/ethnicity, length of time in CNICS, and CNICS site. fAdjusted for educational attainment and family history of breast cancer. gAdjusted for age, race, gender, insurance status, and site. Summary of studies assessing the association of HIV-related stigma and initiation of HIV care or healthcare engagement and retention. CNICS, Centre for AIDS Research (CFAR) Network of Integrated Clinical Systems; NR, not reported; OR, odds ratio. Standard error. b33-item HIV stigma scale used to measure perceived stigma. cHIV barriers to care scale (perceived stigma against people with HIV in their community: 1 item) used to measure perceived stigma. dUnadjusted prevalence ratio (endorsing stigma vs not endorsing stigma). eAdjusted for age, gender identity, sexual orientation, race/ethnicity, length of time in CNICS, and CNICS site. fAdjusted for educational attainment and family history of breast cancer. gAdjusted for age, race, gender, insurance status, and site. Table 3.Summary of studies assessing the association of HIV-related stigma and HIV treatment adherence.PublicationStudy designForm of HIV-related stigmaOutcomeRegression logistic (high vs low stigma levels), OR (95% CI) P value (<0.05 considered statistically significant) Unadjusted analysis Kerrigan et al. (2017), BrazilCross-sectionalUnspecifiedART adherence in last 4 days0.60 (0.39, 0.92)<0.05Halkitis et al. (2014), United StatesCross-sectionalUnspecifiedMissing ART doses in past 4 days1.05 (1.00, 1.10)<0.05Taking ART doses outside specified schedule in past 4 days1.04 (1.01, 1.08)<0.05Failing to follow ART dosing instructions1.08 (1.03, 1.13)<0.01Algarin et al. (2020), United StatesRetrospectiveHigh enactedART non-adherence (<95%)1.71 (1.08, 2.70)0.02Moderate enacted1.15 (0.82, 1.61)0.43Healthcare-specific enacted1.84 (1.15, 2.94)0.01Shrestha et al. (2019), United StatesCross-sectionalEnactedART adherence (≥95%)0.78 (0.51, 1.20)0.27Internalised0.77 (0.54, 1.09)0.14Anticipated0.62 (0.39, 0.98)0.04Meyers-Pantele et al. (2022), United StatesRCTPersonalised (enacted)30-day ART adherence at 3-month follow-up0.98 (0.96, 1.01)>0.0530-day ART adherence at 6-month follow-up0.97 (0.94, 0.99)<0.01Bogart et al. (2015), United StatesCross-sectionalPerceived altera ART adherence0.36 (0.17, 0.76)<0.01Rudolph et al. (2022), United StatesCross-sectionalInternalisedART adherence0.64 (0.43, 0.95)b NR Adjusted analysis Seghatol-Eslami et al. (2017), United StatesCross-sectionalInternalisedART adherence0.61 (0.34, 1.08)c 0.09Turan et al. (2016), United StatesCross-sectionalInternalisedART adherence0.76 (0.58, 0.99)d 0.0420.69 (0.52, 0.91)d,e 0.009Blake Helms et al. (2017), United StatesCross-sectionalInternalisedHIV medication adherence0.54 (0.31, 0.92)f 0.02Turan et al. (2019), United StatesLongitudinalInternalisedART adherence at ~2-year follow-up0.61 (0.45, 0.82)g 0.001Rice et al. (2019), United StatesCross-sectionalAnticipated stigma in healthcare settingART adherence0.64 (NR)h 0.004Enacted stigma in healthcare setting0.58 (NR)i 0.01Shrestha et al. (2019), United StatesCross-sectionalAnticipatedART adherence (≥95%)0.38 (0.18, 0.83)0.02 Logistic (low vs high stigma levels) Yigit et al. (2020), United StatesProspectiveInternalisedART adherence2.05 (1.06, 3.98)j 0.03 Unstandardised analysis Linear (high vs low stigma levels), β value (SE) Stutterheim et al. (2022), EuropeCross-sectionalPerceivedART adherence–0.50 (1.15)NSSeghatol-Eslami et al. (2017), United StatesCross-sectionalInternalisedART adherence self-efficacy–0.43 (NR)0.005Reif et al. (2019), United StatesCross-sectionalInternalisedHIV medication adherence5.61 (1.91)[bivariate coefficient]<0.054.90 (2.13)[multivariate coefficient]<0.05Enacted2.23 (–3.35, –1.12)k [multivariate coefficient]<0.01Rendina et al. (2019), United StatesCross-sectionalUnspecifiedART adherence–0.36 (–1.29, 0.63)k >0.05 Standardised analysis Stutterheim et al. (2022), EuropeCross-sectionalPerceivedART adherence–0.04NSCamacho et al. (2020), United StatesCross-sectionalAnticipatedART adherence0.01 (–0.08, 0.08)k 0.91Kalichman et al. (2022), United StatesCross-sectionalAnticipatedART adherence–0.12 (NR)0.074Enacted–0.11 (NR)0.08Meyers-Pantele et al. (2022), United StatesRCTPersonalised (enacted)7-day ART adherence at 3-month follow-up–0.15 (–0.26, –0.03)k <0.057-day ART adherence at 6-month follow-up0.02 (–0.10, 0.14)k >0.05Rendina et al. (2019), United StatesCross-sectionalUnspecifiedART adherence–0.08 (NR)>0.05Takada et al. (2020), United StatesCross-sectionalUnspecifiedART adherence(30 days before incarceration)–8.10 (–14.97, –1.23)k <0.05Mitzel et al. (2015), United StatesCross-sectionalUnspecifiedSelf-reported HIV medicationadherence in past week–0.34 (NR)<0.01ART, antiretroviral therapy; NR, not reported; NS, not significant; OR, odds ratio; RCT, randomised controlled trial; SES, socioeconomic status.aPerceived alter stigma described as a person within a participant’s social network. bRelative risk (95% CI). cAdjusted by age, race, gender, SES, and ART duration. dAdjusted by race, age, ART duration, injection and use of non-injectable drugs, income, and education. eReported for a subpopulation of women who identified as racial or ethnic minorities in a US cohort of women with HIV. fAdjusted by age, racial identity, gender identity, SES, and ART duration. gAdjusted by ethno-racial identity, age, ART duration, illicit drug use, income, education, and US region (south vs other). hAdjusted by anticipated stigma from all other sources. iAdjusted by enacted stigma from all other sources. jAdjusted by age, race, gender, insurance status, and HIV clinical site. kReported 95% CI. Summary of studies assessing the association of HIV-related stigma and HIV treatment adherence. ART, antiretroviral therapy; NR, not reported; NS, not significant; OR, odds ratio; RCT, randomised controlled trial; SES, socioeconomic status. Perceived alter stigma described as a person within a participant’s social network. bRelative risk (95% CI). cAdjusted by age, race, gender, SES, and ART duration. dAdjusted by race, age, ART duration, injection and use of non-injectable drugs, income, and education. eReported for a subpopulation of women who identified as racial or ethnic minorities in a US cohort of women with HIV. fAdjusted by age, racial identity, gender identity, SES, and ART duration. gAdjusted by ethno-racial identity, age, ART duration, illicit drug use, income, education, and US region (south vs other). hAdjusted by anticipated stigma from all other sources. iAdjusted by enacted stigma from all other sources. jAdjusted by age, race, gender, insurance status, and HIV clinical site. kReported 95% CI. Table 4.Summary of studies assessing the association of HIV-related stigma and virologic suppression.PublicationStudy designForm ofHIV-related stigmaOutcomeRegression logistic (high vs low stigma levels), OR (95% CI) P value (<0.05 considered statistically significant) Unadjusted analysis Algarin et al. (2020), United StatesRetrospectiveHigh enactedUnsuppressed VL (≥200 copies/mL)1.19 (0.75, 1.89)0.46Low/moderate enacted0.96 (0.68, 1.34)0.80Healthcare-specific enacted1.08 (0.66, 1.80)0.75Takada et al. (2020), United StatesCross-sectionalUnspecifiedUnsuppressed VL (<400 copies/mL) at first VL after incarceration0.69 (0.51, 0.93)<0.05Amico et al. (2021), United StatesRCTUnspecifiedHigh-risk vs low-risk viremia (>5000 vs ≤5000 copies/mL)1.19 (0.99, 1.43)0.06Anticipated1.44 (0.88, 2.34)0.14Enacted2.02 (0.96, 4.29)0.05Internalised1.28 (0.94, 1.76)0.12Maragh-Bass et al. (2021), United StatesCross-sectionalEnacted (HIV disclosure stigma experiences)Unsuppressed VL (>40 copies/mL)Men: 0.77 (0.46, 1.28)a >0.05Women: 1.63 (0.79, 3.35)a >0.05Men: 1.57 (0.92, 2.68)b <0.1Women: 1.64 (0.68, 3.95)b >0.05Men: 0.87 (0.51, 1.48)c >0.05Women: 2.06 (0.82, 5.18)c >0.05Enacted (HIV diagnosis stigma experiences)Men: 1.16 (0.79, 1.71)d >0.05Women: 1.35 (0.58, 3.11)d >0.05Matheu et al. (2020), United StatesCross-sectionalAnticipatedLack of virologic suppression (>20 copies/mL)0.96 (0.92, 0.99)0.02 Adjusted analysis Kay et al. (2018), United StatesCross-sectionalEnacted (community)Suppressed VL (<200 copies/mL) vs not suppressed VL (≥200 copies/mL)1.32 (0.51, 3.38)0.57Enacted (healthcare setting)3.23 (1.15, 9.06)0.03Christopoulos et al. (2019), United StatesCross-sectionalInternalisedConcurrent viremia (>200 copies/mL)1.13 (1.03, 1.24)0.01Lipira et al. (2019), United StatesCross-sectionalUnspecifiedVL suppressed (<200 copies/mL) versus not suppressed (≥200 copies/mL)0.93 (0.89, 0.98)<0.01Kalichman et al. (2019), United StatesCross-sectionalInternalisedVL detectable (>100 copies/mL) versus undetectable (<100 copies/mL)Men: 1.29 (0.89, 1.89)>0.05Women: 1.67 (1.02, 2.74)<0.05EnactedMen: 0.99 (0.86, 1.13)>0.05Women: 0.75 (0.58, 0.95)<0.05Christopoulos et al. (2020), United StatesLongitudinalInternalisedUnsuppressed VL (>200 copies/mL)1.16 (1.05, 1.28)0.004 Logistic (low vs high stigma levels) Yigit et al. (2020), United StatesProspectiveInternalisedVL suppressed (<200 copies/mL) versus not suppressed (≥200 copies/mL)8.48 (1.83, 39.28)0.006Zhang et al. (2016), ChinaCross-sectionalPerceivedVL high (>1000 copies/mL) versus low (1–49 copies/mL)0.97 (0.92, 1.03)>0.05Internalised1.01 (0.97, 1.07)>0.05Enacted0.91 (0.60, 1.39)>0.05PerceivedVL medium(50–1000 copies/mL) versus low (1–49 copies/mL)1.05 (1.00, 1.09)<0.05Internalised1.05 (1.02, 1.09)<0.0001Enacted0.75 (0.51, 1.11)>0.05 Unstandardised analysis Linear (high vs low stigma levels), β value (SE) Rendina et al. (2019), United StatesCross-sectionalUnspecifiedUndetectable VL (<200 copies/mL)0.04 (-0.01, 0.08)e >0.05Kalichman et al. (2019), United StatesCross-sectionalInternalisedVL detectable (>100 copies/mL) versus undetectable (<100 copies/mL)Total population: 0.41 (0.14)NRMen: 0.26 (0.16)NRWomen: 0.55 (0.23)NREnactedTotal population: -0.13NRMen: -0.01NRWomen: -0.26NRMiller et al. (2022), United StatesCross-sectionalEnacted (experiencing stigma at the pharmacy)Lower likelihood of self-reported virologic suppression2.09 (0.84)0.013 Standardised analysis Rendina et al. (2019), United StatesCross-sectionalUnspecifiedUndetectable VL (<200 copies/mL)0.19>0.05NR, not reported; OR, odds ratio; RCT, randomised controlled trial; VL, viral load.a1 type of HIV disclosure stigma experience vs no experience of HIV disclosure stigma. b2 types of HIV disclosure stigma experiences vs no experience of HIV disclosure stigma. c≥3 types of HIV disclosure stigma experiences vs no experience of HIV disclosure stigma. dExperience of HIV diagnosis stigma vs no experience of HIV diagnosis stigma. eReported 95% CI. Summary of studies assessing the association of HIV-related stigma and virologic suppression. NR, not reported; OR, odds ratio; RCT, randomised controlled trial; VL, viral load. 1 type of HIV disclosure stigma experience vs no experience of HIV disclosure stigma. b2 types of HIV disclosure stigma experiences vs no experience of HIV disclosure stigma. c≥3 types of HIV disclosure stigma experiences vs no experience of HIV disclosure stigma. dExperience of HIV diagnosis stigma vs no experience of HIV diagnosis stigma. eReported 95% CI. Eligibility criteria were established using 2 standard frameworks tailored to the nature of the specific research questions. These frameworks were not combined; rather, they were applied independently to distinct sets of research questions. For questions focused on prevalence and observational data, we utilised the Condition, Context, and Population (CoCoPop) framework, which is the recommended methodological standard for systematic reviews of prevalence and incidence (Munn et al., 2015). The CoCoPop framework guided the eligibility criteria for the research questions regarding HIV-related stigma prevalence, PROMs, QoL, employment and education, clinical outcomes, mental health, and treatment concepts. For questions evaluating specific impacts or comparative outcomes, we utilised the Population, Intervention, Comparison, Outcome, and Study Design (PICOS) framework. PICOS is a standardised tool widely used in evidence-based medicine to structure clinical research questions and determine literature search eligibility for comparative studies (Moher et al., 2015). The PICOS framework guided eligibility for the research questions examining the impact of HIV-related stigma on medication use for comorbid conditions, substance use (drug and alcohol), and healthcare resource utilisation costs. Inclusion criteria for CoCoPop-assessed research questions included studies reporting HIV-related stigma, which encompassed social attitudes or perceptions toward HIV, fear of discrimination, and anxiety around sharing HIV status among adolescents (aged 12–18 years) and adults (aged >18 years) with HIV. Inclusion criteria for the PICOS-assessed research question included adolescents (aged 12–18 years) and adults (aged >18 years) with HIV. Only studies published in English were included. Record selection and data collection Records were independently screened by 2 reviewers (EM and SJ) until ≥90% inter-rater reliability was achieved. Data were extracted by 1 reviewer and validated by another. Any discrepancies between the 2 reviewers were resolved by consensus or involvement of a third reviewer. Records for data extraction were processed by either a systematic or pragmatic approach, dependent on the research question(s) addressed by the study. A pragmatic approach limited to key outcomes was used for prevalence and PROMs, and a systematic approach was used for the other 2 research questions. As the number of records identified by the SLR was large, the following additional selection criteria (in line with the protocol and agreed upon before data extraction) were applied to prioritise studies for data extraction and synthesis: only studies conducted in Brazil, China, Europe, and the United States; only studies published from 2013 to 2023; and only studies covering the research questions of interest. Additionally, when this SLR did not identify any studies reporting prevalence data in China for 2020 to 2023, an additional study published in 2015 (Zhang et al., 2015) that was identified via literature searches conducted for the other research questions was included. The Joanna Briggs Institute risk of bias tool was used according to study design (Briggs Institute, n.d.) and was conducted by a single reviewer and validated by a second. Data synthesis The results are discussed narratively, as all statistical analyses discussed were conducted by the original study authors and P values were extracted verbatim. Ethics statement This is a systematic literature reviewing previously generated data. Therefore, it was not necessary to seek ethical approval. Results Studies identified The electronic database searches identified a total of 13,902 records (Figure 2). After removal of duplicates and exclusion of irrelevant records at pre-screening, 6181 titles and abstracts were screened against eligibility criteria. Full-text articles were sourced for 1001 records and eligibility criteria were reapplied, leaving 681 records meeting eligibility criteria for inclusion. A further 23 records were identified through supplementary searches. Following the additional refined eligibility criteria, a total of 154 records were included for synthesis. PRISMA flow diagram presenting study flow of this SLR. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; SLR, systematic literature review. aEuropean AIDS Clinical Society Conference, International AIDS Society Conference on HIV Science, International AIDS Conference, Conference on Retroviruses and Opportunistic Infections, International Society for Quality of Life Research, International Association of Providers of AIDS Care, IDWeek, British HIV Association, Professional Society for Health Economics and Outcomes Research. bEuropean AIDS Treatment Group, National AIDS Trust, European Centre of Disease Prevention and Control. Patient-reported outcome measures of HIV-related stigma Patient-reported outcome measures for HIV-related stigma were employed in 148 studies, which used both validated (n = 26) and non-validated (n = 20) tools. Of the 148 studies, 98% (n = 145) were observational studies and 2% (n = 3) were RCTs. Validated measures were used in all 3 identified RCTs and 126/145 observational studies. Of the observational studies, 19 used non-validated measures, and 3 utilised both validated and non-validated measures. Among the observational studies and RCTs, the most commonly used PROM was the Berger HIV stigma scale (n = 75; Figure 3), with 14 studies reporting use of the full 40-item scale, 46 employing the abbreviated scale, and 15 using subscales. The HIV Stigma Framework was the second most commonly used PROM (n = 23). The greatest number of different measures were utilised to assess enacted (n = 22) HIV-related stigma, followed by internalised (n = 18) and perceived (n = 17) HIV-related stigma, suggesting more research interest in assessing these forms of HIV-related stigma. Distribution of patient-reported outcome measures employed in all included studies. Prevalence of HIV-related stigma This SLR identified 15 studies reporting prevalence data, including 7 studies conducted in the United States (Algarin et al., 2020; Beltran et al., 2020; Drumright et al., 2023; Kota et al., 2023; Maragh-Bass et al., 2021; Pearson et al., 2021; Williams et al., 2022), 6 in Europe (Bayes-Marin et al., 2023; Kall et al., 2020; Kampouri et al., 2021; Noori et al., 2022; Stutterheim et al., 2022; Wiginton et al., 2021), 1 in China (Zhang et al., 2015), and 1 in Brazil (Table 1) (Brandelli Costa et al., 2022). Across the 15 studies, 10 different tools were used to measure the prevalence of HIV-related stigma. In general, methodological procedures were well reported across the 15 included studies. However, in a few studies it was unclear whether HIV-related stigma had been measured in a valid and reliable way (eg, studies that used author-developed measures or single statements). The reported prevalence of HIV-related stigma was broad across the multiple stigma types and geographic regions, with ranges of 11% to 94% in the United States (Algarin et al., 2020; Beltran et al., 2020; Drumright et al., 2023; Kota et al., 2023; Maragh-Bass et al., 2021; Pearson et al., 2021; Williams et al., 2022), 10% to 79% in Europe (Bayes-Marin et al., 2023; Kall et al., 2020; Kampouri et al., 2021; Noori et al., 2022; Stutterheim et al., 2022; Wiginton et al., 2021), and rates of 72% and 15% in China and Brazil, respectively (Brandelli Costa et al., 2022; Zhang et al., 2015). Overall, studies assessed the prevalence of enacted (n = 7), internalised (n = 6), anticipated (n = 5), perceived (n = 4), unspecified (n = 3), and personalised (n = 2) stigma. The single study conducted in China reported prevalence data for internalised HIV-related stigma only (72%) (Zhang et al., 2015); in the United States and Europe, the prevalence of internalised stigma was 11% to 35% (n = 4) (Drumright et al., 2023; Kota et al., 2023; Pearson et al., 2021; Williams et al., 2022) and 27% to 57% (n = 1) (Noori et al., 2022), respectively. Although most studies focused on general populations of people with HIV, elevated HIV-related stigma levels were also observed in specific subgroups, such as transgender women, in whom stigma rates ranged from 27% to 94% (n = 1), and men who have sex with men, in whom perceived stigma levels in San Francisco rose from 16% in 2014 to 23% in 2017 (n = 1) (Beltran et al., 2020; Kota et al., 2023). Additionally, the prevalence of enacted stigma in healthcare settings in the Netherlands increased between 2007 (hospital, 26%; dentist, 29%; general practitioner [GP], 19%) and 2019/2020 (hospital, 34%; dentist, 34%; GP, 23%) (Stutterheim et al., 2022). Clinical burden of HIV-related stigma HIV-related stigma and healthcare engagement and retention Eleven studies from the United States (n = 9) (Christopoulos et al., 2019; Hussen et al., 2015; Molina et al., 2018; Pearson et al., 2021; Petroll et al., 2023; Reif et al., 2019; Rice et al., 2017; Takada et al., 2020; Yigit et al., 2020), Europe (n = 1) (Wiginton et al., 2021), and Brazil (n = 1) (Kerrigan et al., 2017) evaluated the association of HIV-related stigma and healthcare engagement and retention, including HIV-specific healthcare engagement and retention (Figure 4; Table 2). Most studies used validated scales to measure HIV-related stigma, and one study created a survey based on the Healthcare Stigma/Discrimination scale from the 2015 HIV Stigma Index (Wiginton et al., 2021). Several outcomes were used to assess healthcare engagement and retention, including missed HIV care appointments in the last 6 months, poor HIV care retention (≥2 missed primary care visits), and ≥1 missed appointment in the last 3 months. Higher HIV-related stigma levels were significantly associated with reduced engagement and retention in general care (2/11 studies) (Molina et al., 2018; Wiginton et al., 2021) and HIV-specific healthcare (8/11 studies) (Christopoulos et al., 2019; Hussen et al., 2015; Kerrigan et al., 2017; Pearson et al., 2021; Petroll et al., 2023; Reif et al., 2019; Rice et al., 2017; Yigit et al., 2020). Clinical burden of HIV-related stigma. OR, odds ratio. aDecreased outcomes (eg, attending HIV primary care appointments); increased outcomes (eg, missing HIV care and treatment visits). bIncludes β value −0.04 (Molina et al., 2018). cIncludes β value (range): −8.10 to −0.15 (Bogart et al., 2015; Camacho et al., 2020; Halkitis et al., 2014; Molina et al., 2018). dIncludes β value (range): 2.23 to 5.61 (Brandelli Costa et al., 2022). eIncludes β value (range): −0.50 to 0.01 (Stutterheim et al., 2022; Rendina et al., 2019; Rice et al., 2019; Turan et al., 2019). fIncludes β value 2.09 (Kalichman et al., 2019). gIncludes β value 0.04 (Turan et al., 2019). hIncludes β value −0.26 (Turan et al., 2019). The majority of studies (7/11) examined the association between higher internalised HIV-related stigma levels and retention and engagement in healthcare in the United States, with 6/7 focusing on HIV care specifically. Three studies reported statistically significant associations between higher internalised HIV-related stigma levels and poorer attendance at HIV primary care appointments (Christopoulos et al., 2019; Hussen et al., 2015; Pearson et al., 2021). Rice et al found that higher internalised stigma levels were significantly associated with lower HIV visit adherence (β value [SE], −0.04 [0.02]; P = 0.04) (Rice et al., 2017). In agreement with these findings, Reif et al reported higher internalised stigma levels were significantly associated with missing HIV medical appointments in the last 6 months (OR [SE], 0.59 [0.14]; P < 0.05) (Reif et al., 2019). Additionally, Yigit et al demonstrated that lower internalised HIV-related stigma levels were significantly associated with higher HIV visit adherence in a 48-week study period (OR [95% CI], 2.17 [1.09, 4.35]; P = 0.03) (Yigit et al., 2020). HIV-related stigma and ART adherence and viral suppression The association between HIV-related stigma and ART adherence was examined in 20 studies across the United States (n = 18) (Algarin et al., 2020; Blake Helms et al., 2017; Bogart et al., 2015; Camacho et al., 2020; Halkitis et al., 2014; Kalichman et al., 2022; Meyers-Pantele et al., 2022; Mitzel et al., 2015; Reif et al., 2019; Rendina et al., 2019; Rice et al., 2019; Rudolph et al., 2022; Seghatol-Eslami et al., 2017; Shrestha et al., 2019; Takada et al., 2020; Turan et al., 2016; Turan et al., 2019; Yigit et al., 2020), Europe (n = 1) (Stutterheim et al., 2022), and Brazil (n = 1; Figure 4; Table 3) (Kerrigan et al., 2017). Each of the studies reported measures of HIV-related stigma using validated scales. Outcomes for ART adherence varied between studies and included missing ART doses, taking doses outside of the specified schedule, ART non-adherence (<95%), and ART adherence (≥95%). Overall, higher HIV-related stigma levels were significantly associated with suboptimal ART adherence in 15/20 studies (Algarin et al., 2020; Blake Helms et al., 2017; Bogart et al., 2015; Halkitis et al., 2014; Kerrigan et al., 2017; Meyers-Pantele et al., 2022; Mitzel et al., 2015; Reif et al., 2019; Rice et al., 2019; Seghatol-Eslami et al., 2017; Shrestha et al., 2019; Takada et al., 2020; Turan et al., 2016; Turan et al., 2019; Yigit et al., 2020). Internalised stigma and its association with ART adherence was the most commonly assessed and was evaluated in 8 studies in the United States. Of these studies, 6 reported significantly poorer or suboptimal ART adherence in individuals reporting high internalised stigma levels (Blake Helms et al., 2017; Reif et al., 2019; Rudolph et al., 2022; Seghatol-Eslami et al., 2017; Turan et al., 2016; Turan et al., 2019). One study by Yigit et al reported a statistically significant association between lower internalised HIV-related stigma levels and increased likelihood of ART adherence (Yigit et al., 2020). Fourteen studies reported data on the association between HIV-related stigma and viral suppression in the United States (n = 13) (Algarin et al., 2020; Amico et al., 2021; Christopoulos et al., 2019; Christopoulos et al., 2020; Kalichman et al., 2019; Kay et al., 2018; Lipira et al., 2019; Maragh-Bass et al., 2021; Matheu et al., 2020; Miller et al., 2022; Rendina et al., 2019; Takada et al., 2020; Yigit et al., 2020) and China (n = 1; Table 4) (Zhang et al., 2016). Generally, the identified studies used validated scales to measure HIV-related stigma, except for Maragh-Bass et al, which employed author-developed tools based on existing methods and literature (Maragh-Bass et al., 2021). Higher HIV-related stigma levels were significantly associated with a higher (or unsuppressed) viral load in 79% (n = 11) of studies (Amico et al., 2021; Christopoulos et al., 2019; Christopoulos et al., 2020; Kalichman et al., 2019; Kay et al., 2018; Lipira et al., 2019; Matheu et al., 2020; Miller et al., 2022; Takada et al., 2020; Yigit et al., 2020; Zhang et al., 2016). Researchers in a US study modelled individual- and community-level associations of viral load results with income inequality and stigma scores (Kalichman et al., 2019). Interestingly, the study found that women with detectable viral loads (>100 copies/mL) experienced significantly greater internalised stigma levels and significantly lower enacted stigma levels, but no significant associations were found with men’s viral loads. HIV-related stigma and CD4+ cell count The evidence identified on the association between HIV-related stigma and CD4+ cell count was limited and inconsistent (n = 2; Figure 4) (Rendina et al., 2019; Zhang et al., 2016), with a US study reporting a significant association between higher unspecified HIV-related stigma levels and lower CD4+ cell count in individuals aged ≥50 years (Rendina et al., 2019). Nonetheless, the study from China found no significant association between perceived, internalised, or enacted HIV-related stigma and CD4+ cell count (Zhang et al., 2016). HIV-related stigma and prevalence of comorbid conditions Thirty studies in the United States (n = 17) (Blake Helms et al., 2017; Brown et al., 2016; Chapman Lambert et al., 2020; Drumright et al., 2023; Felker-Kantor et al., 2019; Gonzalez et al., 2016; Hong et al., 2023; Hussen et al., 2022; Kay et al., 2018; Kreniske et al., 2022; Mitzel et al., 2015; Molina et al., 2018; Rendina et al., 2018; Thompson et al., 2022; Travaglini et al., 2018; Turan et al., 2022; Walsh et al., 2023), Europe (n = 3) (de Daas et al., 2019; Drewes et al., 2021; Murphy et al., 2018), and China (n = 10) (Gao et al., 2018; Greene et al., 2013; Li et al., 2016; Liu et al., 2018; Tao et al., 2017; Wang et al., 2018, 2022; Wu et al., 2015; Yang et al., 2020; Zhang et al., 2016) that reported data on the association between HIV-related stigma and comorbid conditions were identified. Validated scales used to measure HIV-related stigma were consistently implemented across the studies; however, details of the HIV stigma scale used in Li et al were absent (Li et al., 2016). Higher HIV-related stigma levels were significantly associated with depression (n = 15; Table 5) (Brown et al., 2016; Chapman Lambert et al., 2020; Felker-Kantor et al., 2019; Hong et al., 2023; Hussen et al., 2022; Kay et al., 2018; Li et al., 2016; Liu et al., 2018; Mitzel et al., 2015; Molina et al., 2018; Murphy et al., 2018; Rendina et al., 2018; Walsh et al., 2023; Yang et al., 2020; Zhang et al., 2016) and anxiety (n = 10) (Blake Helms et al., 2017; Brown et al., 2016; Felker-Kantor et al., 2019; Hong et al., 2023; Hussen et al., 2022; Li et al., 2016; Murphy et al., 2018; Rendina et al., 2018; Yang et al., 2020; Zhang et al., 2016), which was consistent across subpopulations and geographic regions. Higher HIV-related stigma levels were significantly associated with post-traumatic stress disorder (n = 3) (Gao et al., 2018; Gonzalez et al., 2016; Travaglini et al., 2018) and neurocognitive decline (n = 1) (Thompson et al., 2022). Additionally, individuals with higher HIV-related stigma levels were significantly more likely to have suicidal ideation (n = 4) (Kreniske et al., 2022; Wang et al., 2018, 2022; Wu et al., 2015). Table 5.Summary of studies assessing the association of HIV-related stigma and depression.PublicationStudy designForm ofHIV-related stigmaMeasure and outcomeRegression logistic (high vs low stigma levels),OR (95% CI) P value (<0.05 considered statistically significant) Unadjusted analysis Chapman Lambert et al. (2020), United StatesCross-sectionalAnticipated (family)PHQ-8; higher score on the depression scale1.42 (0.20, 1.69)<0.05Anticipated (friends)1.53 (1.27, 1.84)<0.05Anticipated (healthcare provider)1.09 (0.86, 1.38)>0.05Enacted1.90 (1.35, 2.67)<0.05Anticipateda 1.98 (1.33, 2.96)<0.05Anticipatedb 1.45 (1.03, 2.05)<0.05Internalised2.67 (1.86, 3.75)<0.05Felker-Kantor et al. (2019), United StatesCross-sectionalPerceivedHADS; higher score on depression scale2.05 (1.25, 3.35)c <0.01Personalised/enacted1.72 (0.99, 2.90)c >0.05Anticipateda 1.44 (0.91, 2.27)c >0.05Anticipatedb 1.70 (1.09, 2.66)c <0.05Internalised1.93 (1.29, 2.90)c <0.001Li et al. (2016), ChinaCross-sectionalEnactedCES-D; higher score on depression scale8.59 (2.55, 28.89)0.001Tao et al. (2017), ChinaCross-sectionalPerceivedHADS; classified as having borderline or suspected depression1.05 (1.03, 1.07)d NRVicarious1.08 (1.05, 1.12)d Vicarious (healthcare)1.13 (1.07, 1.20)d Vicarious (community/family)1.19 (1.12, 1.28)d Internalised1.11 (1.08, 1.14)d Internalised (contact avoidance)1.18 (1.12, 1.23)d Internalised (shame/guilt)1.21 (1.15, 1.26)d Unspecified1.04 (1.03, 1.05)d Liu et al. (2018), ChinaCross-sectionalPerceivedBurns Depression Checklist; higher score on depression scale (score >11)1.11 (1.06, 1.16)NR Adjusted analysis Drumright et al. (2023), United StatesLongitudinalInternalisedNR; higher score on depression scale1.60 (1.39, 1.85)e NR1.36 (1.27, 1.45)f Unstandardised analysis Linear (high vs low stigma levels), β value (95% CI) Kay et al. (2018), United StatesCross-sectionalEnacted (community)PHQ-9; higher score on depression scale1.75 (0.50)g <0.001Enacted (healthcare)1.76 (0.79)g 0.03Molina et al. (2018), United StatesCross-sectionalEnactedPHQ-8; higher score on depression scale0.45 (NR)<0.001Turan et al. (2022), United StatesCross-sectionalEnacted (healthcare)CES-D; higher score on depression scale3.78 (2.50, 5.07)h NR3.10 (1.77, 4.43)i Anticipated (healthcare)1.5 (0.83, 2.16)h 1.31 (0.64, 1.98)i Rendina et al. (2018), United StatesCross-sectionalAnticipated (situational)ODSIS; experiencing depression concurrently to stigma event0.01 (−0.06, 0.08)>0.05Anticipated (individual)0.03 (-0.20, 0.26)>0.05Anticipated (situational)Subsequent nighttime experiences of depression after afternoon stigma event0.04 (−0.03, 0.10)>0.05Anticipated (individual)−0.02 (−0.25, 0.21)>0.05Internalised (situational)Experiencing depression concurrently to stigma event0.22 (0.11, 0.33)<0.01Internalised (individual)0.24 (-0.01, 0.48)>0.05Internalised (situational)Subsequent nighttime experiences of depression after afternoon stigma event0.11 (0.01, 0.22)<0.05Internalised (individual)0.31 (0.00, 0.62)<0.05Brown et al. (2016), United StatesCross-sectionalPersonalisedCCAD; more depression symptoms0.92 (0.65, 1.19)<0.05Anticipateda 1.26 (0.75, 1.76)<0.05Internalised1.63 (1.31, 1.96)<0.05Anticipatedb 0.91 (0.66, 1.17)<0.05Unspecified0.52 (0.39, 0.65)<0.05PersonalisedCES-D; more depression symptoms0.52 (0.35, 0.69)<0.05Anticipateda 0.71 (0.39, 1.02)<0.05Internalised0.92 (0.71, 0.13)<0.05Anticipatedb 0.52 (0.36, 0.68)<0.05Unspecified0.29 (0.21, 0.38)<0.05Hong et al. (2023), United StatesCross-sectionalUnspecifiedPHQ-9; higher score on depression scale0.24 (0.05)g <0.001Hussen et al. (2022), United StatesCross-sectionalUnspecifiedCESD-R; higher score on depression scale10.31 (NR)0.012Murphy et al. (2018), EuropeCross-sectionalEnactedHADS; higher score on depression scale0.15 (0.02, 0.28)NRAnticipated−0.08 (−0.26, 0.09)Internalised0.4 (0.26, 0.54)Yang et al. (2020), ChinaCross-sectionalInternalisedCESD-10; higher score on depression scale4.40 (0.74)g <0.001Liu et al. (2018), ChinaCross-sectionalPerceivedBurns Depression Checklist; higher score on depression scale (score >11)0.10 (0.02)g <0.001 Standardised analysis Walsh et al. (2023), United StatesCross-sectionalPerceivedPHQ-9; higher score on depression scale0.29 (0.05)j <0.0010.12 (0.05)k 0.003Mitzel et al. (2015), United StatesCross-sectionalUnspecifiedCES-D; higher score on depression scale0.49 (NR)<0.01Hussen et al. (2022), United StatesCross-sectionalUnspecifiedCESD-R; higher score on depression scale5.43 (2.12)g 0.012Murphy et al. (2018), EuropeCross-sectionalEnactedHADS; higher score on depression scale0.15 (NR)<0.05Anticipatedb −0.06 (NR)NRInternalised0.36 (NR)<0.001Zhang et al. (2016), ChinaCross-sectionalPerceivedCESD-10; higher score on depression scale0.20 (0.15, 0.25)<0.0001Internalised0.29 (0.25, 0.32)<0.0001Enacted2.23 (1.86, 2.61)<0.0001CCAD, Costello-Comrey Anxiety and Depression scale; CES-D, Center for Epidemiologic Studies Depression Scale; CESD-R, Center for Epidemiologic Studies Depression Scale-Revised; CESD-10, Center for Epidemiologic Studies Depression Scale, 10- item version; HADS, Hospital Anxiety and Depression Scale; IHS, internalized HIV stigma; NR, not reported; ODSIS, Overall Depression Severity and Impairment Scale; OR, odds ratio; PHQ-8, Patient Health Questionnaire-8; PHQ-9, Patient Health Questionnaire-9.aAnticipated stigma reported as “disclosure concerns.” bAnticipated stigma reported as “concern with public attitudes.” cRelative risk ratio (95% CI). dOne-point increase in stigma score versus one-point increase in the HADS scale. eAdjusted rate ratio: conditional logistic regression for IHS score >2. fAdjusted rate ratio: Poisson regression stigma score. gStandard error (SE). hRegression coefficients reported from moderation analysis examining the association between experienced stigma and resilience, and the effect their interaction has on depressive symptoms. iRegression coefficients reported from moderation analysis examining the association between experienced stigma and optimism, and the effect their interaction has on depressive symptoms. jSimple linear regression, explored bivariate associations; standard error in parentheses. kMultiple linear regression; considered predictors simultaneously; standard error in parentheses. Summary of studies assessing the association of HIV-related stigma and depression. CCAD, Costello-Comrey Anxiety and Depression scale; CES-D, Center for Epidemiologic Studies Depression Scale; CESD-R, Center for Epidemiologic Studies Depression Scale-Revised; CESD-10, Center for Epidemiologic Studies Depression Scale, 10- item version; HADS, Hospital Anxiety and Depression Scale; IHS, internalized HIV stigma; NR, not reported; ODSIS, Overall Depression Severity and Impairment Scale; OR, odds ratio; PHQ-8, Patient Health Questionnaire-8; PHQ-9, Patient Health Questionnaire-9. Anticipated stigma reported as “disclosure concerns.” bAnticipated stigma reported as “concern with public attitudes.” cRelative risk ratio (95% CI). dOne-point increase in stigma score versus one-point increase in the HADS scale. eAdjusted rate ratio: conditional logistic regression for IHS score >2. fAdjusted rate ratio: Poisson regression stigma score. gStandard error (SE). hRegression coefficients reported from moderation analysis examining the association between experienced stigma and resilience, and the effect their interaction has on depressive symptoms. iRegression coefficients reported from moderation analysis examining the association between experienced stigma and optimism, and the effect their interaction has on depressive symptoms. jSimple linear regression, explored bivariate associations; standard error in parentheses. kMultiple linear regression; considered predictors simultaneously; standard error in parentheses. All 9 studies that assessed higher internalised stigma levels and depression found significant associations (United States, n = 5 (Brown et al., 2016; Chapman Lambert et al., 2020; Drumright et al., 2023; Felker-Kantor et al., 2019; Rendina et al., 2018); Europe, n = 1 (Murphy et al., 2018); China, n = 3 (Tao et al., 2017; Yang et al., 2020; Zhang et al., 2016)), with 5 showing consistent findings in specific populations of people with HIV, including women, (Brown et al., 2016) men who have sex with men (Murphy et al., 2018; Tao et al., 2017; Yang et al., 2020), and gay and bisexual men (Rendina et al., 2018). Additionally, significant associations with higher unspecified or overall HIV-related stigma levels were found in several populations of people with HIV, including women (Brown et al., 2016), gay, bisexual, and other Black men who have sex with men (Hong et al., 2023; Hussen et al., 2022), and men who have sex with men (Mitzel et al., 2015; Tao et al., 2017). Internalised HIV-related stigma was also found to be associated with increased anxiety in all assessed studies (United States, n = 5 (Blake Helms et al., 2017; Brown et al., 2016; Drumright et al., 2023; Felker-Kantor et al., 2019; Rendina et al., 2018); Europe, n = 1 (Murphy et al., 2018); China, n = 2 (Yang et al., 2020; Zhang et al., 2016)). Furthermore, unspecified stigma was associated with severe but not moderate anxiety in specific populations of people with HIV, including young Black men who have sex with men as well as young, Black gay and bisexual men (Hussen et al., 2022). HIV-related stigma and QoL Associations between HIV-related stigma and HRQoL or QoL outcomes were identified in 27 studies in the United States (n = 12) (Brown et al., 2023; Chapman Lambert et al., 2020; Cramer et al., 2017; Fekete et al., 2016; Hong et al., 2023; Hussen et al., 2022; Kamen et al., 2016; Kay et al., 2018; Slater et al., 2013; Slater et al., 2015; Travaglini et al., 2018; Walsh et al., 2023), Europe (n = 6) (de Daas et al., 2019; Dibb, 2018; Drewes et al., 2021; Fumaz et al., 2019; Nilsson Schönnesson et al., 2022; Stutterheim et al., 2022), China (n = 8) (Chen et al., 2022; Liu et al., 2013; Song et al., 2016; Wen et al., 2013; Yang et al., 2020; Zhang et al., 2016; Zhao et al., 2019; Zhu et al., 2020), and Brazil (n = 1) (Kerrigan et al., 2017). Among the 27 studies, 19 different HRQoL measurement tools were used to assess general (16) and HIV-related (3) HRQoL. HIV-related stigma was measured using validated tools, excluding 2 studies where reporting was unclear (Fumaz et al., 2019; Liu et al., 2013), and 1 study measured stigma using a tool that was not specific to the context of HIV-related stigma (Kay et al., 2018). Internalised (n = 7) (Chapman Lambert et al., 2020; Chen et al., 2022; Cramer et al., 2017; Dibb, 2018; Drewes et al., 2021; Nilsson Schönnesson et al., 2022; Zhang et al., 2016) and perceived (n = 7) (Chen et al., 2022; Dibb, 2018; Kamen et al., 2016; Liu et al., 2013; Stutterheim et al., 2022; Wen et al., 2013; Zhang et al., 2016) HIV-related stigma were the most reported stigma types associated with general HRQoL. Higher internalised HIV-related stigma levels were significantly associated with lower general HRQoL (n = 5) (Chapman Lambert et al., 2020; Chen et al., 2022; Cramer et al., 2017; Drewes et al., 2021; Zhang et al., 2016) and lower HIV-related QoL (n = 6) (Brown et al., 2023; Fumaz et al., 2019; Slater et al., 2013; Slater et al., 2015; Yang et al., 2020; Zhu et al., 2020). Additionally, higher perceived stigma levels were significantly associated with lower general HRQoL (n = 6) (Chen et al., 2022; Kamen et al., 2016; Liu et al., 2013; Stutterheim et al., 2022; Wen et al., 2013; Zhang et al., 2016) and lower HIV-related HRQoL (n = 2) (Song et al., 2016; Walsh et al., 2023). Of 6 studies, 5 revealed significant associations between higher HIV-related stigma levels and worsened social or family functioning (Greene et al., 2013; Kay et al., 2018; Nilsson Schönnesson et al., 2022; Wang et al., 2019; Wen et al., 2013). This SLR did not identify any studies reporting on the association between HIV-related stigma and discrimination, and only 1 study suggested that higher HIV-related enacted stigma levels are associated with increased unemployment, increased part-time work, and lower likelihood of making a median to high income (Zhang et al., 2016). Economic outcomes and medication use for comorbid conditions No studies were identified by this SLR that reported an association between HIV-related stigma and interventions for comorbid conditions or healthcare resource utilisation and direct or indirect costs (economic outcomes). Drug, substance, and alcohol use Six studies reported data on the association between HIV-related stigma and drug, substance, and alcohol use (United States, n = 5 (Drumright et al., 2023; Felker-Kantor et al., 2019; Lipira et al., 2020; Schafer et al., 2022; Sizemore et al., 2020); China, n = 1 (Zhang et al., 2016)). All studies evaluated for drug, substance, and alcohol use employed validated scales to measure HIV stigma. Data were limited and inconsistent, which may be due to differing methodologies, study populations, and countries of origin. For example, in US studies, higher internalised HIV-related stigma levels were associated with binge alcohol consumption (adjusted rate ratio [95% CI], 1.32 [1.12, 1.55]), at-risk alcohol consumption (1.15 [1.01, 1.31]) (Drumright et al., 2023), and significantly increased risk of hazardous drinking (relative risk [95% CI], 1.60 [1.17, 2.19]; P < 0.01) (Felker-Kantor et al., 2019). Conversely, the study conducted in China reported that higher internalised HIV-related stigma levels marginally decreased the chance of using alcohol; although significance should be interpreted with caution as the 95% CI of the adjusted OR touches the line of null effect (adjusted OR [95% CI], 0.98 [0.96, 1.0]; P < 0.05) (Zhang et al., 2016). Statistically significant associations with alcohol use and enacted, anticipated, perceived, or unspecified HIV-related stigma were not found. A US study found that higher internalised HIV-related stigma levels were associated with use of methamphetamine (adjusted rate ratio [95% CI], 1.35 [1.12, 1.62]) and opioids (1.50 [1.04, 2.16]), but not cocaine (1.13 [0.89, 1.44]) (Drumright et al., 2023). Higher unspecified HIV-related stigma levels were significantly associated with recreational marijuana use in the past 30 days in gay men, bisexual men, men who have sex with men, and transgender women newly diagnosed with HIV in another US study (OR [95% CI], 1.07 [1.02, 1.12]; P = 0.007) (Schafer et al., 2022). Additionally, high unspecified stigma levels were significantly associated with substance use in adults aged ≥50 years with HIV (standardised β, 0.22; P = 0.029) (Sizemore et al., 2020). No significant associations between high HIV-related stigma (internalised, enacted, or perceived) levels and drug use were observed in the study conducted in China (Zhang et al., 2016). Discussion HIV-related stigma remains an ongoing international challenge. Despite global efforts to reduce stigma and discrimination among people with HIV, we found substantial evidence to support that HIV-related stigma remains prevalent and is negatively associated with clinical and QoL outcomes among people with HIV. Among identified studies, HIV-related stigma was associated with reduced HIV-specific healthcare engagement and retention in 73% (8/11), ART adherence in 75% (15/20), virologic suppression in 79% (11/14), and HIV-related QoL in 86% (6/7) of studies. Furthermore, HIV-related stigma was significantly associated with depression (15/15) and anxiety (10/10) in all studies reporting P values. The data identified in this SLR suggest that the development and implementation of effective interventions to address HIV-related stigma remain an unmet need. Internalised HIV-related stigma was the most frequently assessed form of HIV-related stigma identified across the 4 research questions studied. Hedge et al noted that internalised stigma continues to be an issue among people with HIV, while other types of stigma, such as enacted stigma, may be less frequent or severe than experienced in the past (Hedge et al., 2021). Internalised stigma was also associated with compromised healthcare, a reluctance to engage with HIV testing services, and disengagement from medical services among people with HIV and disengagement from HIV prevention services among individuals with a greater likelihood of HIV acquisition. High HIV-related internalised stigma prevalence (72%) was identified in a study from China (Zhang et al., 2015), with ranges of internalised stigma prevalence in the United States and Europe of 11% to 35% (Drumright et al., 2023; Kota et al., 2023; Pearson et al., 2021; Williams et al., 2022) and 27% to 57%, respectively (Noori et al., 2022). These data suggest there may be cultural differences between Eastern and Western populations that may affect the experience of internalised HIV-related stigma and highlight the importance of considering cultural factors when measuring and interpreting prevalence across geographic regions. Distinct cultural frameworks likely drive these geographic disparities (Aung et al., 2023; Handayani et al., 2021). In Eastern cultures, religious beliefs (eg, karma, divine punishment) cause individuals to internalise an HIV diagnosis as a moral failing (Aung et al., 2023; Handayani et al., 2021; Raya & Nilmanat, 2021). Furthermore, collectivist norms and the preservation of social standing inextricably link personal standing to family reputation (Handayani et al., 2021). This dynamic transforms an HIV diagnosis into a familial threat, leading to what is known as a ‘spoiled identity’ within the community (Raya & Nilmanat, 2021), and driving more severe self-stigmatisation than in Western societies, where individualistic values and HIV advocacy offer a buffer (Operario et al., 2022). However, as the prevalence data from China identified in this SLR date back to 2015, comparisons with more recent Western data should be interpreted with caution. The overall prevalence of HIV-related stigma was broad across stigma types and geographic regions; yet the methods used to measure prevalence were inconsistent across included studies, making it difficult to draw accurate comparisons. A plethora of measures to assess HIV-related stigma exist, with a recent SLR reporting 19 different PROMs utilised across 45 studies (Zhang et al., 2024). Due to the many methods used to assess HIV-related stigma, comparability across studies is challenging; thus, having a common starting point could promote internationally comparable data on HIV-related stigma (Ferguson et al., 2022). Importantly, accuracy and reproducibility are key to obtaining reliable and valid results when selecting PROMs (Zhang et al., 2024). However, researchers and clinicians are limited when selecting the most appropriate PROM by the lack of data on the different types of HIV-related stigma tools utilised in people with HIV across geographies and populations. These data emphasise the importance of employing standardised, validated measures to accurately track and compare the prevalence of HIV-related stigma across geographic regions and populations in future studies. Additionally, high HIV-related stigma levels were reported by specific populations including transgender women and men who have sex with men, which may be attributed to intersecting stigmas related to gender identity and sexual orientation (Layland et al., 2020). Among UNAIDS’ top-line targets for 2025 is for 95% of people with HIV to be on treatment and 95% to maintain viral suppression (UNAIDS, 2020). Our findings support the hypothesis that HIV-related stigma hinders achievement of these targets. Higher HIV-related stigma levels across the various forms were associated with reduced HIV care engagement and retention, suboptimal treatment adherence, and unsuppressed viral load. Engagement with the HIV care continuum can be an overwhelming experience for people with HIV and involves initiating lifelong ART, regular HIV clinic visits, and shared decision-making about managing their HIV (Chapman Lambert et al., 2020). Switching from daily oral ART to a cabotegravir plus rilpivirine long-acting (CAB+RPV LA) regimen has been shown to reduce the proportion of participants feeling stigmatised by HIV treatment (Valenti et al., 2024). At baseline, 18% of participants switching from daily oral ART to CAB+RPV LA reported feeling always or often stigmatised by HIV treatment (N = 308), and by Month 12 of CAB+RPV LA treatment, this number was reduced to <2% of participants (N = 229). Qualitative literature suggests this reduction is primarily driven by the elimination of daily pills, which significantly alleviates concerns regarding unintentional status disclosure (Erguera et al., 2024; Kerrigan et al., 2018). Removing these medications relieves the daily psychological burden and constant mental reminders of living with a stigmatised illness, allowing individuals to create psychological distance from the daily experience of living with HIV (Erguera et al., 2024). Furthermore, participants receiving CAB+RPV LA had improved adherence (74%; N = 1245) compared with participants receiving oral ART (30%; N = 1275), evaluated by proportion of days covered (Garris et al., 2024). These data suggest that switching from daily oral ART to a long-acting injectable may be a treatment option to increase adherence and engagement in care by reducing HIV-related stigma. Enacted HIV-related stigma in the healthcare setting can manifest as refusal of treatment and failure to protect HIV status confidentiality, whereas enacted stigma in community settings may manifest as expression of negative attitudes toward people with HIV and social isolation and rejection in places of public accommodation (Kay et al., 2018). Importantly, this SLR identified associations between high enacted stigma levels in the healthcare setting and unsuppressed viral load, which have important implications for healthcare providers to recognise and mitigate HIV-related stigma in healthcare settings. Consistent with previous research on HIV-related stigma and prevalence of mental health conditions (Chambers et al., 2015; Rueda et al., 2016), our findings indicate that high HIV-related stigma levels are associated with an increased prevalence of mental health conditions, including depression, anxiety, suicidal ideation, and post-traumatic stress disorder. Additionally, mental health conditions, including major depression, among people with HIV have been associated with increased morbidity, mortality, and worsened outcomes along the entire HIV care continuum (Fuenmayor & Cournos, 2022). This SLR did not identify any evidence linking HIV-related stigma with physical conditions of interest, including cardiovascular disease, hypertension, diabetes, dyslipidemia, obesity, chronic renal disease, metabolic syndrome, or bone disease, indicating an area of future research focus. Reducing HIV-related stigma and improving HRQoL among people with HIV are key to achieving the UNAIDS well-being targets (UNAIDS, 2020). In studies examining the association between HIV-related stigma and HRQoL, data trends indicate that higher stigma levels are associated with worsened general and HIV-specific HRQoL outcomes. Previous research has demonstrated that HIV is associated with lower HRQoL (Bing et al., 2000; Liu et al., 2006), and HRQoL is directly associated with clinical outcomes in people with HIV (Call et al., 2000; Penedo et al., 2003). The presence of social support can greatly impact the QoL in people with HIV by contributing to the development of resilience and combating the mental health aspects of the disease; nevertheless, HIV-related stigma within social networks of people with HIV can result in strained relationships and isolation (Brown et al., 2023). Our data support this result, as this SLR identified trends between higher HIV-related stigma levels across various forms and worsened social functioning outcomes. HIV-related stigma profoundly impairs social cognition and social functioning (Akınkoç et al., 2025; Earnshaw & Chaudoir, 2009; Turan et al., 2017). Anticipating stigma triggers defensive cognitive adaptations, including hypervigilance to rejection and pervasive mistrust (Turan et al., 2017). This altered cognition drives behavioural withdrawal, self-isolation, and the breakdown of support networks (Rueda et al., 2016; Turan et al., 2017). As our findings indicate, this isolation extends into broader societal participation, creating significant barriers to employment, career advancement, and engagement with the healthcare system (Aung et al., 2023; Rueda et al., 2016). Ultimately, this degradation of social functioning acts as a primary catalyst for the worsened mental health and clinical outcomes observed across the literature (Rueda et al., 2016; Turan et al., 2017). Drug, substance, and alcohol use are more common in people with HIV compared with the general population (Galvan et al., 2002; Justice et al., 2010; Shiau et al., 2017), which is of particular interest as they have been associated with HIV-related mortality (High et al., 2012), suboptimal antiretroviral adherence (Hendershot et al., 2009), and increased risk of HIV transmission (Scott-Sheldon et al., 2013; Xu et al., 2014). However, the evidence identified in this SLR was limited and inconsistent. Some studies reporting a significant association focused on specific populations such as gay men, bisexual men, men who have sex with men, and transgender women who may be more prone to substance use due to intersectional stigma (Earnshaw, 2020). In contrast, a study from China reported that higher internalised and perceived HIV-related stigma levels marginally decreased the likelihood of alcohol use (Zhang et al., 2016). The authors suggested that social alcohol consumption is common in China and people with HIV may employ coping strategies other than alcohol use, as people with HIV on ART are advised to moderate their alcohol intake to avoid medication side effects. Although this SLR only identified 1 study reporting the association of HIV-related stigma and employment, Perri et al found that HIV-related stigma was described as the greatest barrier to gaining employment among 35 interviews of people with HIV (Perri et al., 2021). Additionally, stigma or discrimination due to HIV status hinders access to employment, job retention, and career advancement, according to a report by the International Labour Organisation (Internal Labour Organisation, 2018). Thus, HIV-related stigma or discrimination can lead to job loss and prevent career progression in people with HIV. The findings of this SLR emphasise the extensive impact that HIV-related stigma has on the lives of people with HIV and demonstrate that the development and implementation of effective tools to tackle stigma are imperative to achieving the UNAIDS 2030 targets. Discussions regarding stigma should be implemented in the healthcare setting and regularly incorporated into routine clinic visits with people with HIV, as there is increasing evidence on the value of supportive and de-stigmatising HIV services in differing sociocultural settings (Nyblade et al., 2009). Importantly, a specific instrument or PROM may not be necessary to alleviate HIV-related stigma in the healthcare setting, as these measures are generally used to provide evidence of HIV-related stigma at the population level (Antela et al., 2022). Opening lines of communication regarding stigma in patient-provider conversations may be an effective tool to attenuate HIV-related stigma and promote the achievement of the UNAIDS 95-95-95 targets. At the individual level, increasing awareness among healthcare workers of what HIV-related stigma is and the benefits of reducing it may open lines of communication between healthcare workers and people with HIV (Nyblade et al., 2009). Additionally, stigma interventions in the healthcare setting should address fears around occupational acquisition and provide opportunities for healthcare workers to reflect on attitudes toward people with HIV (Geter et al., 2018; Stutterheim et al., 2014). Interventions focused on building knowledge around HIV generally reduced HIV-related stigma (Loutfy et al., 2015); therefore, people with HIV who have better coping strategies, education, and more support may experience reduced HIV-related stigma. Specifically, individual-level interventions like resilience training utilise adaptive cognitive-behavioural skills to mitigate the psychological impact of both internalised and enacted stigma (Li et al., 2022). While the majority of studies used validated tools, such as the Berger HIV stigma scale, a number of studies utilised non-validated, author-developed scales, thus rendering comparisons across studies difficult as reliability in data may differ. Researchers should be encouraged to use newer, more contemporary validated tools to support consistent reporting and ensure comparisons in data are feasible across studies. Although this SLR utilised robust methodology and provided a large overview of several topics connected to HIV-related stigma, it does have limitations. It is possible that some publications may not have been identified and more recent evidence may have been published after May 2023. Due to the large number of studies identified, the evidence was refined so that only studies from the United States, Europe, China, and Brazil were included in data synthesis. These specific regions were purposefully selected to capture a diverse cross-section of socioeconomic statuses, cultural frameworks, and healthcare system contexts. Therefore, only a portion of global evidence has been examined. The geographic scope was limited to the United States and Europe (high-income), and Brazil and China (upper-middle income). Although these regions provide a diverse outlook of global healthcare infrastructures, the exclusion of low- and middle-income countries remains a limitation and may affect global generalisability of findings. Despite these limitations, this review captured a broad evidence base and provides a starting point for further research into individual topics of interest pertaining to HIV-related stigma. In conclusion, the substantial evidence identified by this SLR suggests that HIV-related stigma is a significant issue for people with HIV and negatively impacts QoL, mental health, employment, and clinical outcomes. These findings also underscore the importance of integrating stigma considerations into the dialogue between physicians and people with HIV to foster shared decision-making on treatment and support. We identified several evidence gaps, including associations between HIV-related stigma and the prevalence of physical comorbid conditions and interventions for these conditions, discrimination, and economic outcomes. Considerations for future research include the development of holistic interventions that combine individually targeted strategies (such as resilience training) with broader structural interventions. These considerations allow for exploration of intersectionality, as HIV-related stigma is frequently compounded by intersecting stigmas related to race, gender identity, sexual orientation, and socioeconomic status. Furthermore, while individual coping mechanisms can mitigate personal burden, the broader structural context remains a key driver of discrimination. Addressing stigma at the institutional and policy level is likely necessary to achieve a meaningful reduction in prevalence. Future work could further account for governance diversity across geographic settings, recognising how varying state laws, healthcare policies, and political frameworks either mitigate or reinforce societal stigma against people with HIV. Supplementary Material Supplemental Table 3.docx Supplemental Table 3.docx Supplemental Table 2.docx Supplemental Table 2.docx Supplemental Table 1.docx Supplemental Table 1.docx Supplemental Table 4.docx Supplemental Table 4.docx